Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.62 USD
Change Today -0.42 / -2.79%
Volume 146.9K
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

versartis inc (VSAR) Snapshot

Open
$15.07
Previous Close
$15.04
Day High
$15.07
Day Low
$14.47
52 Week High
07/8/14 - $29.93
52 Week Low
05/26/15 - $14.13
Market Cap
427.9M
Average Volume 10 Days
341.4K
EPS TTM
$-2.37
Shares Outstanding
29.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERSARTIS INC (VSAR)

Related News

No related news articles were found.

versartis inc (VSAR) Related Businessweek News

No Related Businessweek News Found

versartis inc (VSAR) Details

Versartis, Inc., a development stage company, operates as an endocrine-focused biopharmaceutical company in the United States. The company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 3 clinical trials for the treatment of growth hormone deficiency. It develops drug candidates that it has licensed from Amunix Operating, Inc. The company was founded in 2008 and is headquartered in Menlo Park, California.

39 Employees
Last Reported Date: 05/11/15
Founded in 2008

versartis inc (VSAR) Top Compensated Officers

Co-Founder and Senior Scientific Advisor to t...
Total Annual Compensation: $410.0K
Chief Financial Officer
Total Annual Compensation: $305.0K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $270.0K
Compensation as of Fiscal Year 2014.

versartis inc (VSAR) Key Developments

Versartis, Inc. Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015

Versartis, Inc. announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported loss from operations of $22,281,000, net loss and comprehensive loss of $22,006,000, net loss attributable to common stockholders of $22,006,000, or $0.79 basic and diluted share compared to the loss from operations of $7,583,000, net loss and comprehensive loss of $19,426,000, net loss attributable to common stockholders of $44,985,000, or $16.13 basic and diluted share for the same quarter a year ago.

Versartis, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM

Versartis, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Jay P. Shepard, Chief Executive Officer, President, Director, Member of Nominating and Corporate Governance Committee and Member of Compensation Committee.

Versartis, Inc., Q1 2015 Earnings Call, May 06, 2015

Versartis, Inc., Q1 2015 Earnings Call, May 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VSAR:US $14.62 USD -0.42

VSAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VSAR.
View Industry Companies
 

Industry Analysis

VSAR

Industry Average

Valuation VSAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERSARTIS INC, please visit www.versartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.